Physician profile
Roy Jackel
NPI 1003895103
$2,971.05
in general payments reported to CMS, 2019-2025
19 companies · $742 in 2025
The $742 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $266 · 2021: $536 · 2022: $397 · 2023: $177 · 2024: $283 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $928.41 | 2019-2025 | Qelbree |
| Abbvie INC. | $455.25 | 2021-2025 | |
| Sk Life Science, INC. | $211.59 | 2022-2023 | Xcopri |
| Biogen, INC. | $170.57 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $153.28 | 2021 | |
| Tg Therapeutics, INC. | $140.00 | 2024 | |
| Greenwich Biosciences, INC. | $140.00 | 2019 | |
| Allergan, INC. | $134.11 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $132.18 | 2020 | |
| Emd Serono, INC. | $125.00 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $110.29 | 2021 | |
| Amgen INC. | $58.71 | 2025 | |
| Argenx US, INC. | $20.87 | 2022 | |
| Boston Scientific Corporation | $18.83 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $12.84 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Impel Pharmaceuticals LLC | $7.85 | 2024 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Jackel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.